What is a stock summary page? Click here for an overview.
Business Description
Faron Pharmaceuticals Oy
ISIN : FI4000153309
Description
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.79 | |||||
| Equity-to-Asset | -0.78 | |||||
| Debt-to-Equity | -1.24 | |||||
| Debt-to-EBITDA | -0.55 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 10.9 | |||||
| 3-Year EPS without NRI Growth Rate | 9.7 | |||||
| 3-Year FCF Growth Rate | 11.8 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.09 | |||||
| Quick Ratio | 1.09 | |||||
| Cash Ratio | 0.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.8 | |||||
| Shareholder Yield % | -10.82 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -132.53 | |||||
| ROIC % | -256.64 | |||||
| 3-Year ROIIC % | 619.02 | |||||
| ROC (Joel Greenblatt) % | -7688.7 | |||||
| ROCE % | -693.96 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -12.88 | |||||
| EV-to-EBITDA | -13.06 | |||||
| EV-to-Forward-EBITDA | -5.13 | |||||
| EV-to-FCF | -12.22 | |||||
| Earnings Yield (Greenblatt) % | -7.76 | |||||
| FCF Yield % | -8.26 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:FPHAF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Faron Pharmaceuticals Oy Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | - | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -0.01 | ||
| 3-Year Sortino Ratio | -0.01 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | - | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 3.3 - 3.3 | ||
| Shares Outstanding (Mil) | 63.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Faron Pharmaceuticals Oy Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Faron Pharmaceuticals Oy Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Faron Pharmaceuticals Oy Frequently Asked Questions
What is Faron Pharmaceuticals Oy(FPHAF)'s stock price today?
The current price of FPHAF is $3.30. The 52 week high of FPHAF is $3.30 and 52 week low is $3.30.
When is next earnings date of Faron Pharmaceuticals Oy(FPHAF)?
The next earnings date of Faron Pharmaceuticals Oy(FPHAF) is 2025-08-27.
Does Faron Pharmaceuticals Oy(FPHAF) pay dividends? If so, how much?
Faron Pharmaceuticals Oy(FPHAF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers